Fluella-fighting fleas have been used for decades to treat fevers, colds, and other illnesses, but they are now also used to fight the flu and other viruses.
A new study, however, suggests that the fleas may also be helpful in preventing the spread of pandemic flu.
The study, led by the University of Florida, is published in the Journal of Infectious Diseases.
The researchers used flea and mosquito control systems to test the effectiveness of the vaccine on two different flu strains, a coronavirus and a H5N1.
The team found that the vaccine worked against the coronaviruses but not the H5Ns.
They also found that there was no benefit to using the vaccine against the H7N9 strain of coronaviral infection, which is currently the most prevalent strain in the U.S. and the world.
The results are significant because flu season is approaching and there is little information about how well the vaccine would work in preventing pandemic influenza.
The authors of the study say that the next steps are to assess whether the vaccine is safe and effective and to determine whether the vaccines effectiveness can be extended to other flu strains.
The Flea and Mosquito Control Systems for Coevolving H5-N1 Influenza Vaccine study is published by Infectious Disease Sciences.
It is the first comprehensive study to compare the effectiveness and safety of different flea, mosquito, and flu vaccine types.
Previous studies have looked at different types of flea-borne viruses, such as H5s and H7s, in different settings.
Fleas are typically very tolerant of a vaccine and, once in the body, can be passed on to others.
However, there are some types of mosquitoes that are resistant to vaccines, such in the genus H5.
Mosquitoes are often infected with viruses like H7, so the vaccine could be ineffective against other types of viruses, like H5, the authors of this new study say.
The vaccine was also effective in treating the coronivirus, the researchers say, but not against the other H5 strains.
They say that, in order to be more effective, the vaccine should be more tolerant of virus-specific immune responses and be administered during a time of low circulating virus circulating, when the immune system is at its peak.
They add that this study has provided valuable information that can be used to design effective flu vaccines.
A study published in August in the journal Nature showed that a vaccine made from the same strains as the vaccine used in the Florida study could be administered to more than 40 percent of people who are already vaccinated against the flu.
This new study is the largest to date to look at whether the flu vaccine could help prevent the spread and spread of H5 pandemic strains.
A Cochrane review published in January found that inactivated influenza vaccines were safe and that the influenza vaccine was more effective than placebo at preventing the emergence of influenza infections in vaccinated subjects.
The Cochrane team, however the team of researchers at the University at Albany, did not study flu vaccines made from other flu viruses.
The Florida study found that when the vaccine was given inactivated in a population of about 200 people, it stopped coronavirin-induced fever, but it did not stop influenza-induced pneumonia or pneumonia-like illness.
The next steps for the team include developing a vaccine that is more tolerant to the virus.
It could be tested on more than 100,000 people to see if the vaccine has the same effect.